CRDL vs. HUMA, AURA, ETON, TSHA, HRTX, ATXS, CMPS, CMPX, TECX, and ESPR
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Humacyte (HUMA), Aura Biosciences (AURA), Eton Pharmaceuticals (ETON), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Astria Therapeutics (ATXS), COMPASS Pathways (CMPS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Cardiol Therapeutics (NASDAQ:CRDL) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.
In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 3 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.16 beat Humacyte's score of 0.63 indicating that Cardiol Therapeutics is being referred to more favorably in the media.
12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 11.2% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cardiol Therapeutics has higher earnings, but lower revenue than Humacyte. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Cardiol Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Humacyte received 12 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 69.64% of users gave Humacyte an outperform vote while only 65.85% of users gave Cardiol Therapeutics an outperform vote.
Cardiol Therapeutics' return on equity of -194.40% beat Humacyte's return on equity.
Cardiol Therapeutics presently has a consensus target price of $8.40, suggesting a potential upside of 650.00%. Humacyte has a consensus target price of $13.71, suggesting a potential upside of 338.16%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Humacyte.
Summary
Humacyte beats Cardiol Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRDL) was last updated on 3/19/2025 by MarketBeat.com Staff
